Focusing on a $651m market, growing due to increased life expectancy and diseases related to ageing, REGEMAT 3D develops biofabrication devices to create tissues and organs, accelerating research in the laboratory. With 2019 sales of c. €682,9k, their devices are now being used in >25 countries.
Research on cells and biomaterials to better understand the behaviour of living tissues and being able to regenerate them has traditionally been done using mainly 2D cultures. Our Bioprinters and Bioreactors are giving researchers access to use 3D printing with biomaterials and cells that are able to mirror the structure of living tissue.
Since launching in 2015, we have sold to more than 100 research institutions and pharma companies around the world. This technology ultimately aims to create functional tissues and living organs in the lab that can be transplanted to patients.
Our current global client base includes University Hospital of Basel (Switzerland), Florida Institute of Technology (USA), University of Western Australia and l'Université libre de Bruxelles, ULB.
Last year we turned over sales of c. €682,9k (EBITDA +€85,885.27), and have recently launched a new bioprinter called REG4Life, a new line of Bioreactors (BMAP) and a department to provide our customers with the bioinks and consumables needed for their research.
We believe this is a market that will grow significantly in the coming years and that is why we are raising now to finance our expansion and increase our sales force and marketing, as well as producing more scientific data on the different tissue applications and improving our manufacturing capabilities.